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The field of diabetes is constantly evolving, with numerous new molecules reaching the market in the treatment of type 2 diabetes. Paradoxically, this drug jungle is difficult for the primary care physician and can lead to therapeutic inertia. After the beneficial effect of empagliflozin on cardiovascular outcomes in the EMPA REG Outcome trial in 2015, liraglutide also shows cardiovascular benefits in high risk patients with type 2 diabetes. Therefore, these two studies, led to new recommendations by the Swiss Society for Endocrinology and Diabetes, by notably favouring the prescription of these molecules to type 2 diabetic patients in secondary prevention, after metformin.